IGF-1 LR3 dosing — no validated human dose, and why the numbers that circulate are unreliable

Every dosing question about IGF-1 LR3 traces back to one engineered property: the molecule was modified to bind IGF-binding proteins poorly, which removes the buffer that normally holds circulating IGF-1 inactive and releases it under local control. The practical consequence is that a given microgram amount produces both a stronger and a much longer signal than the same amount of native IGF-1.

This breaks the usual intuition that a small dose is a cautious dose. In the comparative animal work, the prolonged glucose suppression was not proportional to the depth of the initial drop — at doses matched for equal nadir, the binding-resistant variants still produced about twice the cumulative effect (PMID 9415072). Titrating by immediate feel therefore optimises the wrong variable.

There is no human dosing literature for LR3. The published amounts come from the animal comparison described above (PMID 9415072): bolus doses of 20 and 50 µg/kg body weight for the IGFs in pigs (against 3 µg/kg for insulin as a comparator), and 42 to 270 µg/kg in marmosets. Blood was sampled from 30 minutes before to four hours after injection.

Those are per-kilogram research doses in anaesthetised or closely observed animals with serial blood sampling, chosen to characterise a glucose response — not efficacy doses for any endpoint a person would want. Maximum glucose lowering reached 4.8 mmol/L in the pig.

In bodybuilding and research-community logs, IGF-1 LR3 is typically discussed in flat microgram amounts per day rather than per kilogram, most often cited in the range of a few tens of micrograms daily, with advice to begin at the low end. These figures are anecdotal, unvalidated, and not traceable to any trial; different sources give different ranges, and no regulatory body has defined a safe or effective amount for humans.

Three arithmetic failure modes recur in this material and are worth naming because they are the ones that cause harm:

• Microgram versus milligram. These are microgram amounts. A thousand-fold slip in either direction is a single misread character.
• Reconstitution. The delivered amount depends entirely on how much bacteriostatic water was added to the vial. The same syringe mark means different quantities from differently reconstituted vials.
• Syringe units versus volume. Insulin syringes are marked in insulin units, which are a volume proxy, not a mass. Reading them as if they measured peptide is a common source of large overdoses.

Because the analog accumulates a longer effect than its peak suggests, "more to see if it works" is the specific pattern that turns an experiment into a hypoglycemic emergency.

There is a useful comparison available: mecasermin (Increlex), the approved recombinant IGF-1, has a published dosing structure (Increlex label, DailyMed). Its starting range is 0.04 to 0.08 mg/kg twice daily, escalated by 0.04 mg/kg per dose only after at least a week of tolerance, to a ceiling of 0.12 mg/kg twice daily — and if hypoglycemia occurs despite adequate food intake, the dose is reduced.

The part with no community equivalent is the food rule. The label requires dosing within ±20 minutes of a meal or snack and instructs that the dose be withheld entirely if the patient cannot eat, with missed doses never made up. That instruction exists because severe hypoglycemia leading to hypoglycemic seizures has been observed with a molecule that still responds to binding proteins. LR3 does not.

Nothing about IGF-1 LR3 dosing is self-verifying. There is no assay a person can run on the vial, no IGF-1 target to titrate toward, no glucose monitoring built into the practice, and no dataset establishing what any amount does in a human. What is documented is that binding-resistant IGF variants lower glucose more deeply and for far longer than native IGF-1, and that even the regulated version of this molecule carries a meal-timing requirement and a seizure warning. Judgment about whether and how such a compound could ever be used belongs to a qualified medical professional.